Heart failure and obesity: semaglutide improved symptoms and physical capacity

In STEP-HFpEF, symptoms, physical limitation and walking distance improved versus placebo.

STEP-HFpEF studied people with heart failure with preserved ejection fraction and obesity. They received weekly semaglutide or placebo for 52 weeks.

Semaglutide led to larger reductions in symptoms and physical limitation, greater improvement in the six-minute walk test and more weight loss than placebo. The effect held across all obesity classes analysed.

In three points

Human trial, 52 weeks, placebo-controlled
Fewer symptoms and better walking capacity
Consistent results across obesity classes

Compounds mentioned

Semaglutide

Original source: Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
PubMed · New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.